文献速递病毒性肝炎

简化慢性乙型肝炎治疗标准:减少消除障碍

Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination.
PubMed 文献 · Clin Infect Dis · 2023-01-01

基于2016—2020年Quest Diagnostics数据,评估84 916例慢性乙型肝炎患者按AASLD、EASL、APASL和AATA标准符合治疗资格的比例分别为6.7%、6.2%、5.8%和16.4%;不符合标准者中仍有相当比例存在显著纤维化。作者提出逐步简化标准,使符合治疗比例从10.3%升至87.2%。

要点

  • 按AASLD、EASL、APASL、AATA标准,符合治疗者分别占6.7%、6.2%、5.8%、16.4%。
  • 不符合治疗标准者中,显著纤维化比例分别为10.4%、10.4%、10.8%、7.7%。
  • 简化标准后符合治疗比例从10.3%逐步升至14.1%、33.5%、87.2%。

核心结论

  • 大量不符合现有治疗标准的慢性乙型肝炎患者存在显著纤维化;简化标准以治疗所有可检测HBV DNA的患者,将降低评估治疗资格的复杂性和异质性,提高治疗率并推进HBV消除。

研究设计与样本

  • 利用2016—2020年Quest Diagnostics数据,对慢性乙型肝炎患者(相隔≥6个月两次HBV检测阳性[HBV表面抗原、HBV e抗原或HBV DNA])评估治疗资格。

主要发现

  • 在84 916例慢性乙型肝炎患者中,符合AASLD、EASL、APASL和AATA治疗标准的比例分别为6.7%、6.2%、5.8%和16.4%。
  • 在不符合治疗标准的慢性乙型肝炎患者中,显著纤维化(天冬氨酸氨基转移酶血小板比率指数>0.5)比例按AASLD、EASL、APASL和AATA标准分别为10.4%、10.4%、10.8%和7.7%。
  • 在提出的治疗简化方案中,符合治疗的患者比例从步骤1(HBV DNA>20 000 IU/mL,丙氨酸氨基转移酶[ALT]升高)的10.3%增至步骤2(HBV>2000 IU/mL,ALT升高)的14.1%、步骤3(HBV DNA>2000 IU/mL,任何ALT水平)的33.5%和步骤4(可检测HBV DNA,任何ALT水平)的87.2%。

关键数值与推荐

  • AASLD标准:符合治疗资格者占6.7%,不符合者中显著纤维化占10.4%。
  • EASL标准:符合治疗资格者占6.2%,不符合者中显著纤维化占10.4%。
  • APASL标准:符合治疗资格者占5.8%,不符合者中显著纤维化占10.8%。
  • AATA标准:符合治疗资格者占16.4%,不符合者中显著纤维化占7.7%。
  • 简化步骤1至4的符合治疗比例分别为10.3%、14.1%、33.5%和87.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early, sustained hepatitis B virus (HBV) DNA suppression reduces long-term risks of hepatocellular carcinoma. Chronic hepatitis B (CHB) treatment criteria are complex. Simplifying criteria will improve timely linkage to therapy. We evaluated treatment eligibility patterns among US patients with CHB and propose stepwise simplification of CHB treatment criteria. METHODS: Using 2016-2020 Quest Diagnostics data, we evaluated treatment eligibility among patients with CHB (2 positive HBV tests [HBV surface antigen, HBV e antigen, or HBV DNA] ≥6 months apart) using American Association for the Study of Liver Disease (AASLD), European Association for Study of the Liver (EASL), Asian Pacific Association for Study of the Liver (APASL), and Asian American Treatment Algorithm (AATA) criteria. RESULTS: Among 84 916 patients with CHB, 6.7%, 6.2%, 5.8%, and 16.4% met AASLD, EASL, APASL, and AATA criteria, respectively. Among treatment-ineligible patients with CHB, proportion with significant fibrosis (aspartate aminotransferase platelet ratio index >0.5) were 10.4%, 10.4%, 10.8%, and 7.7% based on AASLD, EASL, APASL, and AATA, respectively. In the proposed treatment simplification, the proportion of patients with CHB eligible for therapy increased from 10.3% for step 1 (HBV DNA >20 000 IU/mL, elevated alanine aminotransferase [ALT] level) to 14.1% for step 2 (HBV >2000 IU/mL, elevated ALT level), 33.5% for step 3 (HBV DNA >2000 IU/mL, any ALT level), and 87.2% for step 4 (detectable HBV DNA, any ALT level). CONCLUSIONS: A large proportion of patients with CHB not meeting established treatment criteria have significant fibrosis. Simplifying criteria to treat all patients with detectable HBV DNA will reduce complexity and heterogeneity in assessing treatment eligibility, improving treatment rates and progress toward HBV elimination.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wong RJ, Kaufman HW, Niles JK, et al. Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination. Clin Infect Dis. 2023. PMID: 35594550. doi:10.1093/cid/ciac385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。